Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Rhea-AI Summary

Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has scheduled the release of its first quarter 2025 financial results for Wednesday, May 14, 2025, after market close. The company has noted that it will not hold a conference call this quarter. Investors can access quarterly results and other investor-related information through the Investors section of Clearside's website.

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.

Information about the Company’s quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company’s website.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical (CLSD) release Q1 2025 earnings?

Clearside Biomedical will release its Q1 2025 financial results on Wednesday, May 14, 2025, after the financial markets close.

Will Clearside Biomedical (CLSD) host an earnings call for Q1 2025?

No, Clearside Biomedical has announced they will not be hosting a conference call for the Q1 2025 earnings.

Where can investors find Clearside Biomedical's (CLSD) Q1 2025 financial results?

Investors can access Clearside Biomedical's quarterly results and other investor information in the Investors section of the Company's website.

What is Clearside Biomedical's (CLSD) main business focus?

Clearside Biomedical is a biopharmaceutical company that specializes in revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®).